No Benefit With Intensified Postinduction in Pediatric Standard-Risk Acute Lymphoblastic Leukemia
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Researchers conducted a systematic review to assess outcomes and complications in pregnant women with type 3 von Willebrand disease.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Patients who received aspirin exhibited levels of PAC-1 binding to platelets similar to those seen in healthy control individuals.
Researchers assessed the safety and efficacy of a pretransplant conditioning regimen in patients with aplastic anemia undergoing allogeneic transplantation.
Patients who underwent moderate-intensity endurance training experienced improvements in capillary density and number of capillaries around a fiber.
C-reactive protein and urine albumin/creatinine ratio were associated with increased risk of bleeding in patients with thrombocytopenia due to hematologic malignancy.
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
Patients who received isatuximab experienced a median progression-free survival of 11.5 months compared with 6.5 months in patients who did not receive isatuximab.
Researchers assessed a method of extracting marrow cells and transforming them to promote fetal hemoglobin generation in patients with sickle cell disease.